Literature DB >> 16805724

The levodopa wearing-off phenomenon in Parkinson's disease: pharmacokinetic considerations.

Fabrizio Stocchi1.   

Abstract

Levodopa is the most efficacious treatment in the management of Parkinson's disease. Unfortunately, chronic use of traditional levodopa/dopa decarboxylase inhibitor formulations is associated with the development of complications, such as wearing-off and dyskinesia. In an attempt to avoid these complications, some physicians delay the introduction of levodopa or employ levodopa-sparing strategies; however, these strategies are frequently suboptimal for patients. As most patients require the superior efficacy of levodopa during the course of their disease, an appreciation of the changing response to levodopa over time and an understanding of the pharmacokinetic principles underlying the development of complications such as wearing-off is essential in the long-term management of the patient.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16805724     DOI: 10.1517/14656566.7.10.1399

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  26 in total

1.  Discovery, synthesis, and structure-activity relationship development of a series of N-4-(2,5-dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): characterization of a novel positive allosteric modulator of the metabotropic glutamate receptor 4 (mGlu(4)) with oral efficacy in an antiparkinsonian animal model.

Authors:  Carrie K Jones; Darren W Engers; Analisa D Thompson; Julie R Field; Anna L Blobaum; Stacey R Lindsley; Ya Zhou; Rocco D Gogliotti; Satyawan Jadhav; Rocio Zamorano; Jim Bogenpohl; Yoland Smith; Ryan Morrison; J Scott Daniels; C David Weaver; P Jeffrey Conn; Craig W Lindsley; Colleen M Niswender; Corey R Hopkins
Journal:  J Med Chem       Date:  2011-10-19       Impact factor: 7.446

2.  Health-related quality of life in Parkinson's: impact of 'off' time and stated treatment preferences.

Authors:  Cicely Kerr; Emily J Lloyd; Charlotte E Kosmas; Helen T Smith; James A Cooper; Karissa Johnston; Emma McIntosh; Andrew J Lloyd
Journal:  Qual Life Res       Date:  2015-12-01       Impact factor: 4.147

3.  The Effect of Parkinson Drug Timing on Cardiovascular Response during Treadmill Exercise in a Person with Parkinson Disease and Freezing of Gait.

Authors:  Cheryl M Petersen; Reid Nelson; Teresa M Steffen
Journal:  Physiother Can       Date:  2013       Impact factor: 1.037

4.  The association between adherence to levodopa/carbidopa/entacapone therapy and healthcare utilization and costs among patients with Parkinson's disease: a retrospective claims-based analysis.

Authors:  Thomas E Delea; Simu K Thomas; May Hagiwara
Journal:  CNS Drugs       Date:  2011-01       Impact factor: 5.749

Review 5.  Adjunctive Therapies in Parkinson's Disease: How to Choose the Best Treatment Strategy Approach.

Authors:  Margherita Fabbri; Mario M Rosa; Joaquim J Ferreira
Journal:  Drugs Aging       Date:  2018-12       Impact factor: 3.923

6.  Clinical and pharmacokinetics equivalence of multiple doses of levodopa benserazide generic formulation vs the originator (Madopar).

Authors:  Margherita Torti; Jhessica Alessandroni; Daniele Bravi; Miriam Casali; Paola Grassini; Chiara Fossati; Cristiano Ialongo; Marco Onofrj; Fabiana Giada Radicati; Laura Vacca; Stefano Bonassi; Fabrizio Stocchi
Journal:  Br J Clin Pharmacol       Date:  2019-09-12       Impact factor: 4.335

7.  Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility--an open-label, 6-week study.

Authors:  Karla Eggert; Orjan Skogar; Khaled Amar; Liisa Luotonen; Mikko Kuoppamäki; Mika Leinonen; Helena Nissinen; Wolfgang Oertel
Journal:  J Neural Transm (Vienna)       Date:  2009-12-15       Impact factor: 3.575

Review 8.  Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson's disease.

Authors:  Angelo Antonini; K Ray Chaudhuri; Pablo Martinez-Martin; Per Odin
Journal:  CNS Drugs       Date:  2010-02       Impact factor: 5.749

9.  Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo).

Authors:  Paolo Solla; Antonino Cannas; Francesco Marrosu; Maria Giovanna Marrosu
Journal:  Neuropsychiatr Dis Treat       Date:  2010-09-07       Impact factor: 2.570

10.  Levodopa/carbidopa/entacapone 200/50/200 mg (Stalevo 200) in the treatment of Parkinson's disease: a case series.

Authors:  Kapil D Sethi; Robert A Hauser; Stuart H Isaacson; Terry McClain
Journal:  Cases J       Date:  2009-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.